

Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis

Andrew D. Foers¹ , Alexandra L. Garnham¹ , Gordon K. Smyth² , Susanna M. Proudman³,
Lesley Cheng⁴ , Andrew F. Hill⁴ , Ken C. Pang⁵ , and Ian P. Wicks⁶ 

ABSTRACT. *Objective.* To identify small noncoding RNA (sncRNA) serum biomarkers that predict response to triple disease-modifying antirheumatic drug (DMARD) therapy in patients with early rheumatoid arthritis (RA). *Methods.* Early RA patients entered into a treat-to-target management algorithm, with triple DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine). Patients were assessed following 6 months of therapy and classified as European League Against Rheumatism responders or nonresponders. RNA was isolated from 42 archived serum samples, collected prior to commencement of triple DMARD therapy. Small RNA sequencing was performed and the reads mapped to annotations in a database of human sncRNA. Differential expression analysis was performed, comparing responders ($n = 24$) and nonresponders ($n = 18$). *Results.* Pretreatment levels of 4 sncRNA were significantly increased in nonresponders: chr1.tRNA131-GlyCCC (4.1-fold, adjusted $P = 0.01$), chr2.tRNA13-AlaCGC (2.2-fold, adjusted $P = 0.02$), U2-L166 (6.6-fold, adjusted $P = 0.02$), and piR-35982 (2.4-fold, adjusted $P = 0.03$). 5S-L612 was the only sncRNA significantly increased in responders (3.3-fold; adjusted $P = 0.01$). Reads for chr1.tRNA131-GlyCCC and chr2.tRNA13-AlaCGC mapped to the 5' end of each tRNA gene and were truncated at the anticodon loop, consistent with these sncRNA having roles as 5' translation interfering tRNA halves (tiRNA). *Conclusion.* Pretreatment levels of specific serum sncRNA might facilitate identification of patients more likely to respond to triple DMARD therapy.

Key indexing terms: biomarker, DMARD, rheumatoid arthritis, small noncoding RNA, translation interfering tRNA halves

This work was supported by the Reid Family Trust (IPW) and the Royal Children's Hospital Foundation (KCP).

¹A.D. Foers, PhD, A.L. Garnham, PhD, The Walter and Eliza Hall Institute of Medical Research, and Department of Medical Biology, University of Melbourne, Parkville; ²G.K. Smyth, PhD, The Walter and Eliza Hall Institute of Medical Research, and School of Mathematics & Statistics, University of Melbourne, Parkville; ³S.M. Proudman, MB BS, Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide; ⁴L.Cheng, PhD, A.F. Hill, PhD, Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora; ⁵K.C. Pang, MB BS, PhD, Departments of Paediatrics, Psychiatry and Adolescent Medicine, University of Melbourne, and Murdoch Children's Research Institute, Parkville; ⁶I.P. Wicks, MB BS, PhD, The Walter and Eliza Hall Institute of Medical Research, and Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia.

K.C. Pang and I.P. Wicks contributed equally.

SMP reports grants from Actelion Pharmaceuticals and Melrose, outside the submitted work.

Address correspondence to Dr. I.P. Wicks, The Walter & Eliza Hall Institute, Parkville, VIC 3052, Australia. Email: wicks@wehi.edu.au. Dr. K.C. Pang, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia. Email: ken.pang@mcri.edu.au.

Accepted for publication June 4, 2020.

Blood-based biomarkers can help guide therapy, avoid invasive tissue biopsy, and provide insight into the underlying pathophysiology of chronic inflammatory diseases, such as rheumatoid arthritis (RA). Circulating extracellular small noncoding RNA (sncRNA) have shown promise as novel biomarkers for clinical application^{1,2}. sncRNA include microRNA (miRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), piwi-interacting RNA (piRNA), and small nuclear RNA (snRNA). These sncRNA are attractive as biomarkers due to abundance, stability, and potential to provide information on underlying disease processes¹.

Triple disease-modifying antirheumatic drug (DMARD) therapy with methotrexate (MTX), sulfasalazine, and hydroxychloroquine is an effective treatment regimen for RA³. The efficacy and relative low cost of triple DMARD therapy has led to its uptake as a first-line therapeutic approach for RA. However, a significant proportion of patients do not respond^{4,5}. As a result, these patients can experience disease progression. Currently, there is no way of determining whether an individual is likely to benefit from triple DMARD therapy or would be better managed with alternative treatment from the outset.

A few reports document baseline expression of circulating miRNA as potential indicators of response to various treatment

regimens in RA, mostly focused on the response to biologic agents^{6,7,8,9,10,11}. These studies have been hindered by small patient cohorts and loss of significance following correction for multiple testing. Further, most previous observations have not been validated in independent cohorts.

In this study, using small RNA sequencing (RNAseq), sncRNA expression was quantified in serum samples collected from patients newly diagnosed with RA, prior to the commencement of triple DMARD therapy. Following adjustment for multiple testing, 5 sncRNA were identified that were differentially expressed in patients who subsequently manifested good or nonresponsiveness to triple DMARD therapy.

MATERIALS AND METHODS

Participants. Archived serum samples were obtained from DMARD-naïve patients attending the Early Arthritis Clinic at Royal Adelaide Hospital. These patients met the inclusion criteria for active RA based on the American College of Rheumatology 1987 revised criteria and had disease duration of < 12 months. Patient details and clinical variables are specified in Table 1. To limit variability unrelated to DMARD responsiveness, we restricted our analysis to white women. Serum was aliquoted upon collection and stored at -80°C. All participants subsequently received treatment in accordance with a standardized triple DMARD therapeutic regimen, as previously described¹². Patients were evaluated after 6 months of therapy and classified as European League Against Rheumatism responders (i.e., good or moderate) or nonresponders¹³. The study was approved by Melbourne Health Research and Ethics Committee (2010.293), and by Royal Adelaide Hospital and The Walter and Eliza Hall Institute human research ethics committees.

RNA isolation, sequencing, differential expression, and bioinformatic analysis. RNA was isolated from serum using the Norgen Plasma/Serum Circulating and Exosomal RNA Purification Kit, and cDNA libraries were prepared, uniquely barcoded, and sequenced using an Illumina NextSeq 500. Raw sequencing data has been uploaded to the NCBI Sequence Read Archive (PRJNA602835). Analysis of RNAseq data was performed using R Statistical software v3.4.2 (R Foundation for Statistical Computing).

Table 1. Patient demographics and baseline clinical variables.

	Responders	Nonresponders	P
N	24	18	1
Females, %	100	100	1
Age, yrs	60.4 (14.5)	54.6 (11.5)	0.782
Weeks of polyarthritis	23.9 (19.0)	40.2 (69.5)	0.432
ACPA, % positive	75	52.9	0.189
Rheumatoid factor, % positive	91.7	44.4	0.001
DAS28-ESR	5.7 (1.1)	5.6 (1.3)	0.997
Swollen 28-joint count	9.7 (5.7)	10.0 (7.5)	0.989
Tender 28-joint count	11.9 (6.5)	15.5 (8.6)	0.863
CRP, mg/L	25.5 (22.8)	13.3 (21.1)	0.557
ESR, mm/h	39.5 (30.7)	25.3 (15.0)	0.496
White cell count, 1 × 10 ⁶ cells/mL	8.6 (2.6)	7.4 (3.8)	0.956

Values are expressed as mean (SD) unless otherwise indicated. ACPA and RF positivity analyzed with Fisher exact test. All other variables analyzed with Student *t* test. ACPA: anticitrullinated protein antibody; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor.

Reads were aligned to the human genome hg19, then mapped to annotations within the database of small human noncoding RNA (DASHR)¹⁴. Any RNA that did not achieve a count per million of mapped reads > 1 in at least 12 samples was filtered out from the data, leaving 1487 sncRNA for analysis. Hierarchical clustering and principal component analysis for all 1487 sncRNA analyzed are included in Supplementary Figure 1 (available with the online version of this article). Differential expression analysis was performed using the edgeR and limma software packages. Correlations between RNA expression and Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (ESR) values were calculated using edgeR's likelihood ratio test. *P* values were adjusted using the Benjamini-Hochberg method. Read counts, normalization factors, and proportions of sncRNA biotypes for each sample are specified in Supplementary Table 1 and Supplementary Figure 2. Additional methodological details are located in online Supplementary Data 1.

RESULTS

Five sncRNA are differentially expressed at baseline between responders and nonresponders. To identify sncRNA with expression indicative of subsequent triple DMARD responsiveness, small RNAseq and differential expression analysis was performed on serum obtained from a cohort of early RA patients, prior to commencing triple DMARD therapy. Five sncRNA were identified with an adjusted *P* value (adj *P*) < 0.05 (Supplementary Table 2, available with the online version of this article). These consisted of 2 tRNA, chr1.tRNA131-GlyCCC and chr2.tRNA13-AlaCGC; a 5S rRNA, 5S-L612; an snRNA, U2-L166; and a piRNA, piR-35982 (Figure 1A). Of these, 5S-L612 was elevated in responders, whereas chr1.tRNA131-GlyCCC, chr2.tRNA13-AlaCGC, U2-L166, and piR-35982 were elevated in nonresponders (Figure 1B,C). Analysis details for all 1487 detected sncRNA are specified in Supplementary Table 2.

5' tRNA halves are enriched in nonresponders to triple DMARD therapy. Because circulating tRNA fragments are elevated in various diseases¹⁵, we investigated whether sequencing reads attributed to the 2 differentially expressed tRNA wholly or partially aligned to their respective full-length tRNA genes. Strikingly, all reads attributed to chr1.tRNA131-GlyCCC and chr2.tRNA13-AlaCGC only partially aligned to the full-length gene sequences (Figure 2A). Further, the majority of reads were derived from the 5' end of the tRNA gene and were truncated at the anticodon loop (Figure 2B), consistent with 5' translation interfering tRNA halves (tiRNA)¹⁵.

sncRNA associations with clinical variables. To explore circulating sncRNA as potential biomarkers of disease activity, associations between sncRNA expression and clinical variables were investigated (Supplementary Tables 3–12, available with the online version of this article). chr1.tRNA131-GlyCCC expression was significantly decreased in patients positive for anticitrullinated protein antibody (ACPA) (2.26 log₂-fold; adj *P* = 0.0497) and rheumatoid factor (RF; chr1.tRNA131-GlyCCC (2.57 log₂-fold; adj *P* = 7.15e-5). A significant positive correlation with tender 28-joint count (TJC28; *r* = 0.14, adj *P* = 7.19e-6) was also apparent. piR-35982 was significantly decreased in patients positive for RF (1.36 log₂-fold; adj *P* = 0.049) and showed modest, negative correlations with C-reactive protein




Figure 1. sncRNA differentially expressed between responders and nonresponders. (a) MA plot of counts per million reads (CPM) vs fold change for all 1487 sncRNA analyzed. sncRNA with an adjusted P value < 0.05 are indicated in red and labeled. (b) Supervised heatmap showing relative expression of significantly differentially expressed sncRNA across individual patient samples. Heatmap rows show differentially expressed sncRNA. Heatmap columns represent individual patients. Relative RNA abundance is coloured by Z score as indicated. (c) Box and whisker plots comparing expression and variability of differentially expressed sncRNA. Lower and upper hinges respectively correspond to the first and third quartiles. Whiskers extend from hinges to highest and lowest values that are within $1.5 \times$ IQR. Mean values are indicated.

($r = -0.03$, adj $P = 0.03$) and ESR ($r = -0.06$, adj $P = 0.03$). U2-L166 showed a positive correlation with TJC28 ($r = 0.20$, adj $P = 0.03$).

DISCUSSION

RA is a complex, heterogeneous inflammatory disease. Currently,

there is no way of prospectively determining the optimal therapeutic approach for an individual who is newly diagnosed with RA. Biomarkers that enabled rational selection of therapy at the time of diagnosis would help stratify management of patients with RA. In this study, we identified 5 circulating sncRNA that are differentially expressed between responders




Figure 2. tRNA reads are truncated at the anticodon loop. (a) Alignments of chr1.tRNA131-GlyCCC and chr2.tRNA13-AlaCGC reads against their full-length gene sequence. Chromosomal locations of genes are indicated, and full-length canonical gene sequences are specified. Nucleotide variations from canonical sequence are colored accordingly. (b) Position of sequence reads in relation to tRNA secondary structures. For both tRNA, reads are attenuated at the anticodon loop. Nucleotides within sequencing reads are indicated in black; absent nucleotides are indicated in gray. Nucleotide variations from canonical gene sequence are specified with an asterisk.

and nonresponders to triple DMARD therapy. If confirmed, these circulating sncRNA could help guide rational selection of therapy and provide further information on the underlying biology of treatment responses.

Understanding the physiological functions of sncRNA in RA and/or DMARD pharmacology might also offer new

insights into disease. We found chr1.tRNA131-GlyCCC and chr2.tRNA13-AlaCGC 5' tRNA were significantly elevated in nonresponders to triple DMARD therapy. tRNA are evolutionary conserved RNA that are produced following cleavage of full-length tRNA at the anticodon loop by the RNase angiogenin¹⁵. Fragmentation of tRNA extends tRNA function

beyond facilitating protein synthesis¹⁵, with tRNA having roles in inhibiting protein synthesis, inhibiting apoptosis, and sequestering proteins¹⁵. A recent study reported that a 5'-tRNA-Ala mimic similar to chr2.tRNA13-AlaCGC tRNA enhanced the migratory and invasive capacity of HCT116 colorectal cancer cells¹⁶. Although the biological mechanism underlying this function is unknown, it is conceivable that chr2.tRNA13-AlaCGC might similarly contribute to proinflammatory cell behaviour in RA.

sncRNA are present at high levels in the circulation and form part of ribonucleoprotein complexes, or are associated with high-density lipoproteins or extracellular vesicles¹. Encapsulation or association of sncRNA with extracellular vesicles, high-density lipoproteins, and ribonucleoprotein complexes can facilitate RNA uptake and thereby the functional modification of target cells¹. In this way, circulating sncRNA might be able to regulate cellular physiology. It remains to be determined whether the differentially expressed sncRNA identified in our study have biological function or represent metabolic by-products.

Of note, our results conflict with an earlier report that found expression of miR-16 and miR-223 were increased in the serum of RA patients who responded to conventional DMARD¹⁰. These miRNA were not identified as significantly differentially expressed in our study. Likewise, circulating miRNAs previously reported as correlating with disease activity^{10,17,18} were not confirmed in our study. These differences might be explained by variations in methodology, plus our use of correction for multiple testing, which is especially important for high-throughput RNAseq analyses.

To be of clinical use, biomarkers must have high specificity. Importantly, RA patients with more severe disease are known to be less likely to respond to treatment¹⁹. To this end, sncRNA associated with response to therapy must be distinguished from sncRNA that are associated with more severe disease. We found expression of chr1.tRNA131-GlyCCC 5' tRNA was significantly increased in nonresponders to triple DMARD therapy, with the lowest *P* value of all sncRNA analyzed. Consistent with poorer treatment outcomes for patients negative for ACPA and RF²⁰, levels of chr1.tRNA131-GlyCCC were significantly increased in these patients. Further, a significant positive correlation between chr1.tRNA131-GlyCCC levels and TJC28 scores ($r = 0.14$, $\text{adj } P = 7.19 \times 10^{-6}$) suggests that elevated circulating chr1.tRNA131-GlyCCC 5' tRNA levels might signify increased inflammation. Weaker associations between 5S-L612, chr2.tRNA13-AlaCGC, U2-L166, and piR-35982 expression and clinical variables suggest these sncRNA are more likely to reflect DMARD responsiveness.

In summary, we identified 5 circulating sncRNA in patients with early RA that might represent clinically useful biomarkers of subsequent triple DMARD responsiveness. In addition, sncRNA such as tRNA may play an unappreciated role in the pathogenesis of RA or in the response to treatment. Major strengths of this study include the serial evaluation of a patient cohort treated in a uniform manner and the relatively homogeneous patient group.

Limitations include the need for validation in an independent cohort and the relatively small sample size of exclusively white women. We also found a significant difference in RF positivity between responders and nonresponders in our patient cohort. While RF status is reported to be a poor predictor of MTX response²¹, its ability to predict the response to triple DMARD has not been extensively investigated. The sncRNA identified in this study may provide new insights into the pathogenesis and treatment of RA. Our findings suggest further study of this class of potential biomarkers is warranted in RA.

ACKNOWLEDGMENT

Next-generation sequencing was performed by Stephen Wilcox at the Ian Potter Centre for Genomics within the Walter and Eliza Hall Institute for Medical Research, Victoria, Australia. The authors acknowledge patients who donated samples for this study, and the support of the Reid Family Trust and the Royal Children's Hospital Foundation.

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES

1. Fritz JV, Heintz-Buschart A, Ghosal A, Wampach L, Etheridge A, Galas D, et al. Sources and functions of extracellular small RNAs in human circulation. *Annu Rev Nutr* 2016;36:301-36.
2. Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. *Nat Rev Clin Oncol* 2018;15:541-63.
3. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med* 1996;334:1287-91.
4. Proudman SM, Keen HL, Stamp LK, Lee ATY, Goldblatt F, Ayres OC, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. *Semin Arthritis Rheum* 2007;37:99-111.
5. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. *Arthritis Rheum* 2009;60:1222-31.
6. Duroux-Richard I, Pers YM, Fabre S, Ammari M, Baeten D, Cartron G, et al. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. *Mediators Inflamm* 2014;2014:342524.
7. Piao X, Hu J. Circulating microRNA-125b expression predicts clinical response in patients with rheumatoid arthritis treated by tumor necrosis factor inhibitors. *Int J Clin Exp Pathol* 2017;10:1809-16.
8. Cuppen BV, Rossato M, Fritsch-Stork RD, Concepcion AN, Schenk Y, Bijlsma JW, et al. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis? *Arthritis Res Ther* 2016;18:189.
9. Sode J, Krintel SB, Carlsen AL, Herland ML, Johansen JS, Horslev-Petersen K, et al. Plasma microRNA profiles in patients with early rheumatoid arthritis responding to adalimumab plus methotrexate vs methotrexate alone: a placebo-controlled clinical trial. *J Rheumatol* 2018;45:53.

10. Filková M, Aradi B, Senolt L, Ospelt C, Vettori S, Mann H, et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2014;73:1898-904.
11. Castro-Villegas C, Pérez-Sánchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limón P, et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF α . *Arthritis Res Ther* 2015;17:49.
12. Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ. Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis. *Br J Nutr* 2015;114:885-90.
13. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. *Arthritis Rheum* 1996;39:34-40.
14. Leung YY, Kuksa PP, Amlie-Wolf A, Valladares O, Ungar LH, Kannan S, et al. DASHR: Database of small human noncoding RNAs. *Nucleic Acids Res* 2016;44:D216-22.
15. Schimmel P. The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. *Nat Rev Mol Cell Biol* 2018;19:45-58.
16. Li S, Shi X, Chen M, Xu N, Sun D, Bai R, et al. Angiogenin promotes colorectal cancer metastasis via tiRNA production. *Int J Cancer* 2019;145:1395-407.
17. Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther* 2010;12:R86.
18. Murata K, Furu M, Yoshitomi H, Ishikawa M, Shibuya H, Hashimoto M, et al. Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. *PLoS One* 2013;8:e69118.
19. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. *Arthritis Rheum* 2007;56:3226-35.
20. Pope JE, Movahedi M, Rampakakis E, Cesta A, Sampalis JS, Keystone E, et al. ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI). *RMD Open* 2018;4:e000738.
21. Yu MB, Firek A, Langridge WH. Predicting methotrexate resistance in rheumatoid arthritis patients. *Inflammopharmacology* 2018;26:699-708.